Recursion Pharmaceuticals (RXRX) Enterprise Value (2020 - 2025)
Recursion Pharmaceuticals (RXRX) has disclosed Enterprise Value for 6 consecutive years, with -$747.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 25.19% year-over-year to -$747.9 million, compared with a TTM value of -$747.9 million through Dec 2025, down 25.19%, and an annual FY2025 reading of -$747.9 million, down 25.19% over the prior year.
- Enterprise Value was -$747.9 million for Q4 2025 at Recursion Pharmaceuticals, down from -$663.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$219.1 million in Q1 2021 and bottomed at -$747.9 million in Q4 2025.
- Average Enterprise Value over 5 years is -$483.5 million, with a median of -$475.3 million recorded in 2023.
- The sharpest move saw Enterprise Value crashed 132.47% in 2022, then soared 36.87% in 2024.
- Year by year, Enterprise Value stood at -$516.6 million in 2021, then decreased by 6.7% to -$551.2 million in 2022, then increased by 28.37% to -$394.8 million in 2023, then crashed by 51.32% to -$597.4 million in 2024, then fell by 25.19% to -$747.9 million in 2025.
- Business Quant data shows Enterprise Value for RXRX at -$747.9 million in Q4 2025, -$663.0 million in Q3 2025, and -$528.2 million in Q2 2025.